Moody National Bank Trust Division boosted its position in Geron Co. (NASDAQ:GERN – Free Report) by 76.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 267,629 shares of the biopharmaceutical company’s stock after acquiring an additional 116,074 shares during the period. Moody National Bank Trust Division’s holdings in Geron were worth $947,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of GERN. National Bank of Canada FI increased its holdings in Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the period. Readystate Asset Management LP purchased a new position in shares of Geron during the third quarter valued at approximately $58,000. Rovin Capital UT ADV bought a new position in shares of Geron during the third quarter valued at approximately $62,000. Empowered Funds LLC purchased a new stake in Geron in the third quarter worth $67,000. Finally, Inspire Advisors LLC bought a new stake in Geron in the third quarter valued at $68,000. 73.71% of the stock is owned by institutional investors.
Geron Trading Down 6.0 %
Shares of NASDAQ GERN opened at $2.98 on Tuesday. The company has a market cap of $1.80 billion, a PE ratio of -9.31 and a beta of 0.55. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm’s 50 day moving average price is $3.81 and its 200-day moving average price is $4.22. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34.
Wall Street Analyst Weigh In
GERN has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Geron in a research report on Tuesday, December 10th. Needham & Company LLC lifted their price objective on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday. Scotiabank assumed coverage on Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. Finally, Barclays raised shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and an average target price of $7.25.
Get Our Latest Research Report on GERN
Geron Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
- Five stocks we like better than Geron
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What is the Dogs of the Dow Strategy? Overview and Examples
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What Does a Stock Split Mean?
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN – Free Report).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.